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Duchenne Muscular Dystrophy (DMD) and the murine model mdx are degenerative diseases 
that are characterized by the absence of the protein dystrophin causing membrane instability, 
calcium (Ca
2+
) influx, and progressive muscle wasting. The sarco(endo)plasmic reticulum 
Ca
2+
-ATPase (SERCA) is the enzyme responsible for maintaining low cytosolic Ca
2+
 and is 
dysfunctional in mdx mice, contributing to elevations in cytosolic Ca
2+
.  Sarcolipin (SLN) is an 
endogenous protein regulator of SERCA that reduces SERCA activity by lowering the 
apparent Ca
2+
 affinity of SERCA.  SLN is highly upregulated in mdx muscle, yet when ablated 
from mdx mice a worsened phenotype is observed, possibly due to blunted calcineurin/NFAT 
signaling. Glucocorticoid steroids are the primary therapy for DMD patients and combat the 
dystrophic phenotype in mdx mice.  Glucocorticoid steroids have been shown to stimulate 
calcineurin signaling, which results in the upregulation of utrophin, the homologue of 
dystrophin.  Glucocorticoids also increase the expression of SLN, which may function to 
regulate calcineurin activity. The aim of this study was to determine whether SLN plays a role 
in the positive treatment effects of glucocorticoid steroids in mdx mice. It was hypothesized 
that glucocorticoid treatment would increase SLN expression, stimulate calcineurin activity 
and increase utrophin expression in muscles from mdx mice but not in muscles from mdx mice 
lacking SLN (i.e. mdx/Sln
-/-
).  Here, four week old mdx and mdx/Sln
-/-
 mice were injected with 
either the glucocorticoid, deflazacort (DFZ), or vehicle (VEH) alone for 7 days.  Following 
treatment, soleus (SOL) and diaphragm (DIA) muscles were collected for biochemical and 
histological analyses.  Protein content of SLN, utrophin, calcineurin, SERCA isoforms and 
nuclear factor activation T cell (NFAT), a transcription factor dephosphorylated by calcineurin, 
was determined using western blotting.  Immunofluorescent/histological techniques were used 
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to assess centralized nuclei, collagen infiltration, myosin heavy chain isoform, cross sectional 
area (CSA), and fibre size variability, using the variance coefficient of minimal Feret’s 
diameter.  Activation of the calcineurin/NFAT signaling pathway was also assessed using co-
localization of NFATc1 and DAPI, which stains nuclear DNA. DFZ treatment improved 
several markers of the dystrophic phenotype in both the SOL and DIA, including centrally 
nucleated fibres and collagen infiltration.  There were some muscle-specific differences in fibre 
type distribution between genotypes and treatments but these were mostly minor differences in 
hybrid fibres.  CSA was not affected in the majority of fibre types by DFZ or genotype.  
Unexpectedly, variability in fibre size was not improved by DFZ treatment but was actually 
increased in DFZ treated mdx/Sln
-/-
 DIA compared with VEH.  DFZ increased NFATc1 and 
DAPI co-localization in both mdx and mdx/Sln
-/-
 mice in the SOL only.  However, calcineurin 
content and utrophin in both SOL and DIA were not different between any groups.   SERCA1a 
and SERCA2a content in SOL and DIA were not different between DFZ and VEH treated 
mice, but SERCA1a was lower in the DIA of mdx/Sln
-/-
 mice compared to mdx mice.  DFZ 
treatment increased SLN content in mdx SOL but not in DIA.  In summary, 7 days of DFZ 
treatment improved some histological features of DMD in both mdx and mdx/Sln
-/-
 mice in the 
SOL, which was associated with increased NFATc1 nuclear translocation, suggesting 
increased activation of the calcineurin/NFAT pathway.  Despite histological improvements in 
the DIA with DFZ treatment, the calcineurin/NFAT pathway appeared not to be active in that 
tissue relative to VEH.  Finally, contrary to the main hypothesis, DFZ effects were similar in 
mdx and mdx/Sln
-/-
 mice, suggesting that SLN does not play a role in mediating the positive 
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 Calcium ions (Ca
2+
) are vital in governing physiological processes throughout the body, 
including skeletal muscle, where it acts as an important signaling and regulatory molecule that 
governs excitation-contraction, thermogenesis, second messenger signaling, activation of 
transcription factors and apoptosis [1]. The regulation  of cytosolic Ca
2+
 is critical in the proper 
function of skeletal muscle and loss of Ca
2+
 homeostasis either through impairments in Ca
2+
 
release or uptake have severe implications for muscle health and function. Ca
2+
 reuptake into 
the sarcoplasmic retitculum (SR) is facilitated by the sarco(endo)plasmic reticulum Ca
2+
 
ATPase  (SERCA) and impairments in this enzyme have already been documented in a number 
of muscle diseases, including Duchenne Muscular Dystrophy (DMD) [2].  The gold standard 
therapy for DMD, glucocorticoid steroids, have been shown to alter Ca
2+
 handling and promote 
Ca
2+
 sensitive adaptation pathways, namely the calcineurin/NFAT pathway [3]. Ablation of 
regulators of SERCA is associated with improved Ca
2+
 handling yet paradoxically have a 
worsened disease phenotypes, through the blunting of the calcineurin/NFAT pathway [2, 4]. 
This thesis examines the treatment of mdx mice with glucocorticoids if its positive effects are 
associated with SLN expression.  
Duchenne Muscular Dystrophy  
Muscular dystrophies are a classification of genetic disorders that affect primarily 
skeletal muscle. Duchenne muscular dystrophy (DMD), an X-linked myopathy, is the most 
severe and prevalent of the dystrophies, affecting 1 in 3500 live male births [5]. Symptoms are 
exhibited during childhood and include weakness in limb muscles, scoliosis and impairments 
in ambulation, with onset typically occurring at age 5, leading to wheelchair use by age 12 [5, 
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6]. As a result of the impairments in skeletal muscle, DMD patients suffer from respiratory 
weakness leading to assisted ventilation and respiratory failure [7]. Previously, this was the 
most common cause of death in DMD patients, but due to improvements in respiratory care 
patients are living longer allowing for other developments in the disease [8]. In fact, 
cardiomyopathies have emerged as the leading cause of death in DMD patients, contributing to 
approximately 20% of DMD patient deaths [8, 9].  
DMD is an inherited genetic disease that is a result of an out-of-frame deletion or 
missense mutation in the Duchenne gene at Xp21 [5, 10]. This mutation results in the complete 
lack of the protein dystrophin. Dystrophin is a large (427kDa) structural protein that provides a 
physical link from the extracellular matrix to the cytoskeleton of muscle fibres [6, 10, 11]. 
Dystrophin is an integral component of the dystroglycan complex (DGC), where it connects to 
ɣ-actin through its N-terminus binding domain, and to the β-dystroglycan subunit via its C-
terminus. The β-subunit interacts with the α-dystroglycan subunit, which binds to laminin in 
the extracellular matrix (reviewed in [12, 13]). 
Due to the interaction dystrophin has with the DCG and other associated proteins, 
dystrophin provide stability to muscle fibres during muscle contraction and relaxation [14]. In 
addition, dystrophin provides a communication pathway from inside the myofibre to the 
extracellular matrix and vice versa [15]. Therefore, the loss of dystrophin results in both 
structural instability and impairment in signal transduction (reviewed in [13]).  
In DMD and the commonly used murine model, mdx, there is a complete lack of 
functional dystrophin [16]. In addition, there is a 80-90% down regulation of dystrophin 
associated proteins, such as α and β- dystroglycan which contribute to the pathology of the 
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disease [13]. The pathology of mdx mice and DMD patients possess a number of similar 
markers such as elevated plasma creatine kinase, variability in fibre size, necrosis, macrophage 
invasion, centralized myonuclei, and replacements of muscle tissue with adipose and/or 
connective tissue [17-21]. However, compared with DMD patients, mdx mice have a much less 
severe disease phenotype and relatively normal life spans [18, 19], which has led some 
researchers to utilize other genetic models, most importantly the mdx/utrophin
-/-
 mice [22, 23]. 
Nevertheless, the mdx model still provides researchers with the ability to understand the 
underlying mechanisms and progression of the disease. 
One major reason for the relatively mild disease phenotype of mdx mouse mice is an 
endogenous upregulation of the protein utrophin [23, 24]. Utrophin, previously known as 
dystrophin related protein, is typically expressed at the neuromuscular junctions in healthy 
muscle where it provides vital scaffolding in the post synaptic apparatus [25-27] and is 
expressed beyond the junction in developing muscle [28, 29]. Utrophin does have a similar 
function to dystrophin [30], but expression patters differ between these proteins where 
dystrophin is expressed in both oxidative and glycolytic muscles while utrophin is expressed 
more so in oxidative muscles compared to glycolytic muscles [26, 31]. In human DMD 
patients and mdx mice, utrophin extends beyond the neuromuscular junction when examined 
with immunofluorescent staining [27, 28, 32-34]. This upregulation was thought to be a 
compensatory mechanism to stabilize the sarcolemmal membrane in order to minimize 
contraction induced damage [35]. The ability of utrophin to compensate in stabilizing the 
sarcolemmal membrane then poses as an interesting therapeutic target for DMD [36].   
Like human DMD, mdx mice undergo phases of muscle degeneration and regeneration, 
but unlike humans, mdx mice have an improved regenerative capability and a less severe 
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phenotype in the majority of skeletal muscles [23, 37]. The degeneration in human DMD 
progresses very quickly; causing wheelchair dependence in mid-teens and death by age 30 if 
untreated [38]. Mdx mice on the other hand, exhibit four distinct stages of disease progression. 
From just after birth to approximately 3 weeks of age, mdx mice present very similarly to 
wildtype (WT) littermates, with no differences in fibre size, fibre type distribution or muscle 
damage [34, 39]. At 3-4 weeks of age, mdx mice undergo a substantial degenerative phase [34, 
40, 41], followed by a phase of regeneration until 7 weeks old [17, 20, 42]. After this time 
period, mdx mice exhibit a plateau phase, until 4 to 6 months of age where degeneration is 
matched by regeneration [14, 43]. Following this plateau, mdx mice exhibit degeneration, 
marked by progressive loss of body weight, extensive fibrosis of limb and respiratory muscles, 
decreases in type IIB fibre proportions and ultimately death at approximately 2 years of age 
[43-45].  Therefore, 3-7 weeks of age in mdx mice is an appropriate time frame to examine the 
underlying mechanism of disease progression and how pharmacological interventions affect 
relevant outcomes, while being more correlative to human DMD.   
Calcium Dysregulation and the Progression of DMD  
The impairments in functional capability of those with DMD are attributed to 
progressive muscle weakness and muscle degeneration, caused by extreme membrane 
instability due to the lack of dystrophin. This membrane instability results in an influx of 
extracellular calcium ions (Ca
2+
) and increased ion permeability [11, 46-48]. Contraction 
induced micro-tears in the sarcolemmal membrane lead to the insertion of “leak channels”, 
which reinforces this Ca
2+
 overload within the cytosol [46, 49, 50]. This influx of Ca
2+
 results 




]i) that have cytotoxic effects. Ca
2+
 activated 
proteolytic enzymes, namely calpains and caspases, are increased in DMD and mdx mice 
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which contributes to the degeneration of limb and respiratory muscles [49-53]. The leak 
channels become constantly active by Ca
2+
 activated proteolysis which further promotes 
myofibril degeneration, increases fibrosis and the progression of the disease phenotype [47, 
54]. 
In theory, if calcium reuptake into the SR was able to match this increased influx of 
Ca
2+
 than the Ca
2+
 associated degeneration may be limited, but if Ca
2+
 reuptake into the SR is 
impaired , then increases in cytosolic Ca
2+
 would occur. Ca
2+
 reuptake is facilitated by the 
sarco(endo)plasmic reticulum Ca
2+
 ATPase (SERCA). SERCAs are 110kDa integral 
membrane proteins that pump Ca
2+
 from the cytosol into the SR at the expense of adenosine 
triphosphate (ATP) and are critical in the relaxation of muscle and maintaining cytosolic Ca
2+
 
levels [55-57]. Adult skeletal muscle has two predominate SERCA isoforms, SERCA1a and 
SERCA2a, which are thought to be dependent on fibre type. SERCA1a is primarily expressed 
in fast-twitch muscles and SERCA2a is expressed in slow-twitch muscle [58], however there is 
evidence to show that both SERCA isoforms are expressed within the same fibre type. In 
human vastus lateralis both SERCA1a and SERCA2a are present in type I or type IIA fibres 
[59].  
In mdx mice, SERCA is functionally altered as a result of oxidative damage [60, 61], 
causing sustained elevations in cytosolic Ca
2+
 and further contributing to the progression of the 
disease [2, 62, 63]. Improvements in the dystrophic phenotype have been observed when 
SERCA content is overexpressed [64, 65] or when oxidative damage of SERCA is prevented, 
through the increase of the chaperone protein Hsp72 [66, 67]. Thus, altering SERCA activity or 
content in DMD can normalize cytosolic Ca
2+
 and thus alter the disease phenotype.  
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Sarcolipin in DMD and Calcineurin/NFAT Signaling  
One possible way to alter SERCA activity is through targeting key regulators of 
SERCA, such as sarcolipin (SLN) and phospholamban (PLN). SLN regulates SERCA through 
its physical interaction with the pump [68-71]. SLN is a small, 31 amino acid (6 kDa) protein, 
comprised of a transmembrane, cytoplasmic and luminal domain [72, 73], that inhibits SERCA 
activity by reducing the apparent affinity of SERCA for Ca
2+
 [72, 74-76]. Interestingly, in 
many myopathies, including mdx mice, an upregulation of SLN content is observed [2, 77-80], 





and the activation of Ca
2+
 sensitive pathways. Therefore, one might expect that 
reducing or deleting SLN may improve SERCA function and decrease cytosolic Ca
2+
 content, 
especially as Sln-null (Sln
-/-
) mice show improved Ca
2+
 transport [75, 76].   
In order to test this hypothesis, our lab bred mdx mice with Sln
-/-
 mice, creating a 
progeny of dystrophic mice that completely lack SLN [81]. These mice allowed us to test 
whether improving SERCA function by removing SLN could improve the dystrophic 
phenotype in soleus and diaphragm muscles. Compared with mdx mice, improvements in Ca
2+
 
apparent affinity were observed but maximal SERCA activity was not different in mdx/Sln
-/-
mice [4]. Despite this improvement in calcium handling, mdx/Sln
-/-
 mice had a worse pathology 
than mdx mice, marked by increases in centralized nuclei, increased collagen infiltration and 
elevations in serum creatine kinase (CK). Since mdx/Sln
-/-
 mice also had decreased utrophin 
expression, reduced myofibre size and increased percentages of fast glycolytic fibres, which 
could be indicative of blunted calcineurin/NFAT signaling, it was hypothesized that SLN 





 sensitive serine-threonine phosphatase is comprised of catalytic 
subunit A and a regulatory B subunit. When stimulated by sustained low amplitude elevation in 
Ca
2+
, calmodulin binds to the calcineurin heterodmiers and increases the affinity calcineurin 
has for Ca
2+
 [82-84]. Thus, small elevations in Ca
2+
 can greatly increase calcineurin activity 
[85]. This association dislodges the auto-inhibitory domain of calcineurin A, allowing the 
active site of the catalytic subunit to be opened and calcineurin to dephosphorylate downstream 
targets [86-88]. One of these downstream targets is the family of nuclear factor activating T-
Cells (NFAT), which includes NFATc1-c5 [89], but of these, only NFATc1-c4 is responsive to 
calcineurin [90-93].  
Once dephosphorylated by calcineurin, NFATs translocate to the nucleus where they 
act as transcription factors and promote gene expression [86, 94]. Different isoforms of NFATs 
promote specific gene expression. For example NFATc1 is key in promoting an oxidative 
phenotype of muscle through the transcription of myosin heavy chain I, troponin I and 
myoglobin [92, 95-100]. Interestingly, there is a NFAT binding site in the utrophin A (an 
isoform of utrophin) promoter [101]. Thus when NFATc1 is translocated and an oxidative 
phenotype is promoted, utrophin expression is also expressed [31].  The calcineurin/NFAT 
pathway is sensitive to Ca
2+
 levels and can improve the dystrophic phenotype through utrophin 
expression [101, 102].  
 The potential of SLN upregulation in stimulating calcineurin activity to bring about 
positive adaptations such as utrophin expression is promising. Work performed in our lab 
reinforces the concept that SLN upregulation may serve as compensatory mechanism in 
disease. In mice that overexpress the SLN homologue phospholamban (PLN) in slow-twitch 
muscle (Pln
OE





mice results in further exacerbation of the disease phenotype through blunting of 
the calcineurin/NFAT pathway [103]. These mice lacking SLN showed a delayed fast-to-slow 
fibre type transition, decreases in NFATc1 translocation, and decreases in stabilin-2 content 
(phosphatidylserine receptor required for myoblast fusion specific regulated by NFATc1) 
[104]. Furthermore, Sln
-/-
 mice fail to show the same adaptive responses to functional overload 
of the plantaris and tetonomy (unloading) of the soleus muscle compared with WT controls. In 
the overloaded plantaris muscle, Sln
-/-
 mice showed impairments in calcineurin signaling with 
impaired fast-to-slow fibre transition, no translocation of NFAT into the nucleus or change in 
stabilin-2 compared to sham controls. In the tetonomized soleus, there was no translocation of 
NFAT to the nucleus and no change in stabilin-2, again indicating an impairment of the 
calcineurin/NFAT pathway [104]. 
Furthermore, mice overexpressing SLN show increased calcineurin activity and 
increased NFAT nuclear translocation resulting in an increased oxidative capacity [105]. 
Utrophin expression correlates with oxidative capacity and is regulated by calcineurin-NFAT 
signaling [31]. Collectively, these results highlight the role SLN plays in activating the 
calcineurin/NFAT pathway and thus it is plausible that the upregulation of SLN in mdx mice is 
a compensatory mechanism to activate the calcineurin/NFAT pathway to promote utrophin 




Figure 1.1: Conceptual map of the effect of SLN on calcineurin/NFAT signaling. Black 
solid arrows represent mdx mice which have an intrinsic upregulation of SLN content which is 
associated with increased calcineurin/NFAT signaling that can increase utrophin content. Red 
solid arrow represents mdx/Sln
-/-
 mice which have blunted calcineurin/NFAT signaling that 
results in decreased utrophin content.   
 
Glucocorticoid Steroids in the Treatment of DMD 
Currently, DMD patients undergo several drug and ventilation therapies in order to 
delay wheelchair dependence, improve quality of life and lengthen the life span of patients [8, 
106]. There is no cure for DMD, and until such a time that genetic therapy can be utilized to 
remove the mutation that causes the loss of functional dystrophin in DMD patients, other 
treatments must be used to combat disease progression. Research utilizing the CRISPR-9/Cas9 
technology appears promising in mouse models of the disease, by restoring dystrophin 
expression through the deletion of multiple exons in the DMD gene [107-109]. While these 
genetic therapies are being tested for viability in humans, the current “gold standard” in the 
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treatment of DMD is with glucocorticoid steroids, namely prednisone and its oxazoline 
derivative, deflazacort (DFZ) [110].  
Glucocorticoid steroids are a subclass of corticoid steroids that are endogenously 
expressed in the body. They are secreted by the adrenal cortex in order to maintain metabolic 
homeostasis in the body [111]. Glucocorticoids mobilize glucose as well as amino acids and fat 
stores [112]. Endogenous and synthetic glucocorticoids are capable of diffusing across the 
plasma membrane due to their lipophilic nature in order to interact with their intracellular 
receptors. The inactive receptor is found in the cytosol bound in a complex containing heat 
shock proteins 90 (hsp90), hsp70, hsp56, hsp40, p23, and several immunophilins [113, 114]. 
Once within the cell, glucocorticoids bind to their receptors, which then dissociates from its 
complex. The receptor and ligand then translocate to the nucleus where it acts as a transcription 
factor either through binding directly to DNA or through protein-protein interactions [115].   
In healthy populations and some diseases, glucocorticoids have a catabolic effect on the 
body, with muscle loss typically being a consequence of glucocorticoid use. Elevations in 
endogenous glucocorticoids, such as cortisol, are typically associated with states of muscle 
atrophy and decreased protein synthesis. However, glucocorticoids, namely the synthetically 
derived prednisone and its derivative DFZ, produce paradoxical improvements in DMD 
patients. Several studies saw improvements in muscle strength and prolonged ambulation with 
prednisone or DFZ treatment [116-119]. These benefits were first observed by Drachman et al., 
(1974) where 14 DMD patients treated with prednisone for 28 months showed somewhat 
positive effects. The group concluded that prednisone improved muscle strength, prolonged the 
functional status of the patient for another two years and that this warranted further study in a 
larger population [116]. These positive effects of glucocorticoids were corroborated by several 
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other groups both in human DMD [120-122] and mdx mice [123, 124], but the underlying 
mechanisms remained unknown for some time.   
The selection and dosage of DFZ for this study was based on the study performed by 
St. Pierre et al. (2004), which has examined the underlying mechanism of glucocorticoid 
treatment that will be described below. DFZ is the oxazoline derivative of prednisone, the 
primary prescribed drug for the treatment of DMD. DFZ has been gaining momentum as a 
treatment for DMD, as it is reported to have similar benefits to the dystrophic phenotypes with 
less severe side effects compared to prednisone [125-128]. In addition, it has been reported that 
DFZ may have other beneficial effects to delay the progression of DMD through laminin 
expression and myogenic repair in mdx mice [124]. Although this dosage is higher than what is 
used in humans [125, 128], it was capable of promoting utrophin transcription in the mdx 
model [3].   
Pathways Involved in Glucocorticoid Treatment of DMD 
Glucocorticoid treatments have been shown to increase utrophin expression in mdx 
mice, muscle fibres and myotubes [3, 32, 129], but it was not clear as to how. One potential 
pathway is the calcineurin/NFAT cascade because the utrophin A promoter contains an NFAT 
binding site, thus any activation of this pathway could lead to utrophin transcription [101]. 
Indeed, expression of a constitutively active calcineurin in mice leads to chronic stimulation of 
the calcineurin/NFAT pathway, resulting in upregulation of utrophin protein [101, 130]. When 
these mice are crossbred with mdx mice, the upregulation of utrophin still persists and the 
dystrophic phenotype is mitigated [101, 130, 131]. Blocking this pathway, either through 
inhibition of calmodulin [132] or through pharmacological inhibition of calcineurin with 
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cyclosporine A (CsA) [3, 31, 133], results in reduced utrophin expression and an exacerbation 
of the phenotype.  
Given that activation of calcineurin mitigates the dystrophic phenotype through 
increasing utrophin content, it was hypothesized that glucocortcoids act through this pathway 
to increase utrophin expression [3]. Mdx mice treated with DFZ showed improvements in the 
dystrophic phenotype through decreases in centralized nuclei and fibre size variability, but this 
was completely lost in mdx mice treated with both DFZ and CsA. In this same study, DFZ 
treated dystrophic myotubes showed increased translocation of NFATc1 and calcineurin 
activity [3]. This study provided the first evidence that glucocorticoids increase utrophin 
expression through activating the calcineurin/NFAT pathway thereby improving the dystrophic 
phenotype.  
From this evidence, it stands to reason that altering Ca
2+
 levels to activate calcineurin 
may be a viable approach to increase utrophin expression and mitigate DMD. Interestingly, 
glucocorticoids have been observed to increase SLN content in rat diaphragm. Gayan-Ramirez 
et al. (2000) utilized triamcinolone (a fluorinated glucocorticoid) through intramuscular 
injections for five days and observed a significant increase in SLN mRNA in diaphragm. The 
researchers speculated that an increase in SLN expression might be a compensatory 
mechanism to combat atrophy of the muscle [80]. As described above, given that SLN reduces 
the pumping of Ca
2+
 by SERCA, elevations in SLN could result in increased cytosolic Ca
2+
, 
which would then activate Ca
2+
 sensitive pathways, like the calcineurin/NFAT pathway. 
Therefore, it is possible that increased SLN expression with glucocorticoids might be important 
or even required for activating calcineurin signaling and promoting utrophin transcription (see 




Figure 1.2: Conceptual map of the effect of Sln-ablation on glucocorticoid treatment. 
Black solid arrows represent mdx mice, where DFZ treatment further increases SLN content 
which is associated with increased cytosolic Ca
2+
 and calcineurin/NFAT activity resulting in 
increased utrophin content, which correlates to improved dystrophic phenotype. Red solid 
arrows represent mdx/Sln-/- mice where DFZ treatment does not alter calcineurin/NFAT 
activity or utrophin content, preventing the positive effects of glucocorticoids.  
 
Statement of the Problem 
Glucocorticoid treatment improves dystrophic pathology through calcineurin 
stimulation and increased utrophin expression. Given that SLN overexpression can stimulate 
calcineurin and both DMD and glucocorticoid steroids increase SLN content, the purpose of 
this study was to examine the role of SLN in the therapeutic effects of glucocorticoids in DMD 
using mdx and mdx/Sln
-/-
 mice.  Given that glucocorticoids have been shown to mitigate the 
progression of the disease phenotype and improve ambulation in mdx mice and DMD patients 
[38, 117, 126, 128, 134, 135], but cause muscle atrophy in healthy populations [112, 136-139], 
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healthy wild type (WT) animals were excluded from the study as they would likely produce 
confounding effects that would not be relevant to the main goal of this thesis.  Analyses were 
restricted to soleus (SOL) and diaphragm (DIA) muscles based on two characteristics: 1) the 
presence of SLN and 2) the severity of muscle damage. The soleus and diaphragm both 
expresses SLN protein at a basal state [59, 140, 141] which becomes upregulated in numerous 
disease states including mdx mice. DMD affects limb muscles such as the SOL but the DIA 
muscle is more clinically relevant as DIA of mdx mice presents a similar phenotype to human 
DMD [142]. 
Objectives and Hypotheses  
Objectives 
The objectives for this thesis are as follows: 
i) To compare the effects of DFZ treatment on muscle fibre type distribution, fibre size, 
centralized nuclei, fibrosis and serum creatine kinase between mdx and mdx/Sln
-/-
 mice.  
ii) To compare the effects of DFZ treatment on calcineurin/NFAT signaling between mdx 
and mdx/Sln
-/-
 mice.  
iii) To compare the effects of DFZ treatment on protein expression of SERCA isoforms 




The hypotheses in relation to these objectives listed above: 
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i) DFZ treatment will reduce pathology in both SOL and DIA including decreases in 




ii) DFZ treatment will increase body weight, and both SOL and DIA weight and fibre 
CSA in mdx mice but not mdx/Sln
-/-
 mice.  
iii) DFZ treatment will increase the proportion of slower (type I and IIA) fibres and 
SERCA2a expression and decrease the proportion of faster (type IIX and IIB) fibres 
and SERCA1a expression in mdx mice but not mdx/Sln
-/-
 mice. 
iv)  DFZ treatment will increase SLN content, calcineurin signaling (i.e. decrease p-
NFAT/NFAT and increase NFAT/DAPI co-localization) and utrophin expression in 





Transgenic Animals           




 colonies was established within 
our laboratory as previously described [81]. Two separate colonies were formed: 1) mdx and 




 littermates, which indicates that not all experimental 
animals are littermates and are cousins at best.  Genetic background has been kept consistent 
between colonies, where experimental animals are equal parts C57BL/10ScSn/J: C57BL6/J, 
(50:50) in both mdx and mdx/Sln
-/-
. This was done to reduce the number of culled animals and 
is consistent with the guidelines outlined by the Canadian Council of Animal Care and the 
University of Waterloo Animal Care Committee. Appendix B contains the breeding strategy 
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utilized in this thesis to create mdx and mdx/Sln
-/-
 animals. All animals were housed on a 
standard 12:12-hour light-dark cycle and in an environmentally controlled room. Mice had ad 
libtium access to food and water. To determine genotype, littermate animals were ear notched 
and DNA samples were digested and purified. DNA was amplified through polymerase chain 
reaction (PCR) to identify whether male animals were wild type or mdx. Further details on 
genotyping can be found in Appendix B. All experiments were reviewed and approved by the 
University of Waterloo Animal Care Committee in accordance with Canadian Council on 
Animal Care guidelines.  
 
Experimental Design  
Starting at 4 weeks of age, mdx and mdx/Sln
-/- 
pups (n=20 for each genotype; N=40) 
were injected subcutaneously every day for 7 days with either DFZ (Sigma Aldrich) dissolved 
in sterile saline at a dosage of 1mg/kg body weight (n=10) or saline alone (sham injected, 
n=10). Body weight was monitored throughout the treatment period. Figure 2.1 specifically 
outlines the number of animals in each experimental group.  
Mice were sacrificed 24 hours following the last injection and the intact SOL and DIA 
muscles were excised and either homogenized or mounted for histology and 
immunofluoresence staining. The mounted tissue was embedded in optimal cutting temperature 
compound (OCT) (VWR) (n=10 for each group) and frozen in isopentane chilled in liquid 
nitrogen. Muscle homogenates were prepared by first removing all connective tissue and then 
homogenizing the muscle using a manual glass on glass homogenizer at a 10:1 dilution in cold 
PMSF buffer (250 mM sucrose, 5 mM HEPES, 10 mM NaN3, and 0.2 mM 
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phenylmethanesulfonyl fluoride, pH 7.5). The homogenate was then aliquoted and frozen in 
liquid nitrogen and stored at -80°C for further analysis. 
 
Figure 2.1: Schematic of experimental design and allocation of animals.  
 
Antibodies for Western Blotting and Immunofluorescence 
 Primary antibodies for SERCA isoforms, NFATc1, phosphorylated NFATc1 (p-
NFATc1), calcineurin, α-actin and SLN were utilized in Western blotting. SERCA1a (A52) 
was generously donated by Dr. David MacLennan (University of Toronto). SERCA2a (2A7-
A1), phosphorylated-NFATc1 (PA5-38301) and total NFATc1 (MA3-024) were obtained from 
Pierce. Calcineurin antibody was obtained from Millipore (07-1491) and the primary antibody 
against actin (A4700) was obtained from Sigma Aldrich. The utrophin antibody (610896) was 
obtained from BD Biosciences. The primary antibody for SLN was generated by Lampire 
Biological Laboratories. Secondary antibodies for Western blotting, specifically goat anti-
mouse IgG (peroxidase conjugated; sc-2005) and goat anti rabbit IgG (peroxidase conjugated, 
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sc-2030), were obtained from Santa Cruz Biotechnology (Dallas, TX). For 
immunofluorescence staining, primary antibodies for dystrophin (MANDYS1), MHCI (BA-
F8), MHCIIa (SC-71), MHCIIb (BF-F3), NFATc1 (MA3-024) and utrophin (MANCHO10) 
were obtained from Developmental Studies Hybridoma Bank. Secondary antibodies, Alexa 
Fluor 555 anti-mouse IgG2a, Alexa Fluor 350 anti-mouse IgG2b, Alexa Fluor 488 anti-mouse 
IgG1 and Alexa Fluor 555 anti-mouse IgM were obtained from Molecular Probes Thermo 
Fisher.  
 
Histological and Immunofluorescence Staining  
SOL and DIA were collected from all groups and cut into 10µm thick serial cross 
sections with a cryostat (Thermo Electric) maintained at -20°C. Histological staining included 
haematoxilyn and eosin (H&E) and Van Gieson in order to examine muscle health and fibrosis, 
respectively as described previously [143]. Centralized nuclei counts, representing regenerating 
muscle fibres were determined from H&E stained sections. Images were collected using the 
Nikon microscope linked to a Pixel Linked digital camera and quantified with Image Pro 
PLUS analysis and Image J software.  
Immunofluorescence analysis of myosin heavy chain (MHC) expression was performed 
previously as described by Bloemberg and Quadrilatero [144]. Briefly, slides were blocked in 
10% Goat Serum (Sigma-Aldrich) for one hour at room temperature and then incubated against 
primary antibodies for myosin heavy chain I, IIA, and IIB (see Antibodies section for complete 
list). Sections were then washed with phosphate buffered saline (PBS) three times for five 
minutes and incubated with appropriate fluorescently tagged secondary antibodies for one hour 
19 
 
at room temperature. Sections were again washed following the above procedure and mounted 
with Prolong Gold anti-fade reagent (Molecular Probes) with No.1 coverslips (VWR). Images 
were taken with Axio Observer Z1 fluorescent microscope equipped with standard red, green, 
blue filters, an Axiocam HRm camera and AxioVision Software (Carl Zeiss). These images 
were used to quantify total myofibre number, muscle fibre type distribution, cross sectional 
area (CSA) and minimal Feret’s diamter.  Minimal Feret’s diameter is a common and reliable 
measure of muscular dystrophy, whereby the minimum distance of parallel tangents of 
opposite borders of a myofibre are examined, representing heterogeneity of muscle fibre size 
[17]. The quantification of fibre type distribution and cross sectional area was performed 
utilizing ImageJ software. Analysis of minimal Feret’s diameter was done using ImageJ 
software and coefficient of variance was determined using Microsoft excel.  
To asses NFATc1 nuclear localization (as a marker of calcineurin signaling), 
immunofluorescent detection of NFATc1 and 4',6-diamidino-2-phenylindole, DAPI, a marker 
of nuclear DNA was performed and their co-localization was assessed. This technique utilized 
Pearson’s correlation coefficient to assess whether NFATc1 had translocated to the nucleus. 
Pearson’s correlation coefficient is a measure of linear correlation between two variables, in 
this case DAPI and NFATc1. A value of +1 indicates a positive correlation, 0 indicates no 
correlation and -1 represents a negative correlation. In this technique, 20-40 centralized 
myonuclei (20 for SOL, 40 for DIA) were highlighted at random and NFATc1 colocalization. 
To quantify colocalization of DAPI and NFATc1, muscle sections of both SOL and DIA were 
fixed in 4% paraformaldehyde for 10 minutes and then washed in 1X PBS for 5 minutes three 
times. Following washing, slides were permeabilized with 0.5% Triton X-100 for 30 minutes. 
Sections were again washed for 5 minutes three times and then blocked in 5% goat serum-PBS 
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for one hour. Sections were then incubated overnight at room temperature against primary 
antibodies for NFATc1 (1:50) and α-dystroglycan (1:100) (see Antibodies list for complete 
information). α-dystroglycan is used to visualize individual fibres, in place of traditional 
dystrophin, to specifically measure NFAT levels from myonuclei. After incubation, slides were 
washed in 1X PBS and then incubated against fluorescently tagged secondary antibodies IgG1 
and IgM at a dilution of 1:500 for 1 hour. Slides were again washed in 1X PBS and then 
incubated in 0.3µM DAPI solution for 2 minutes. Slides were then washed in PBS before 
coverslips were adhered to the slides. Images were taken the next day using the confocal Zeiss 
LSM 800 and colocalization was analyzed using ZEN digital imaging software.  
Utrophin expression was also assessed by immunofluorescence by quantifying maximal 
sarcolemmal utrophin fluorescence intensity, adapting a technique from a study performed by 
Banks et al. who measured sarcolemmal dystrophin [145]. This technique not only provides a 
measure of utrophin content but also displays actual localization of utrophin. Briefly, sections 
were blocked in 5% goat serum-PBS for one hour and then incubated with primary antibodies 
for utrophin (1:100) and α-dystroglycan (1:100) for another hour. Slides were then washed in 
1X PBS for 5 minutes three times and then incubated against IgG1 and IgM fluorescently 
tagged secondary antibodies for one hour. Images were taken the next day using the confocal 
Zeiss LSM 800 and analysis was performed using ImageJ computer software (NIH). To 
quantify utrophin, a line was drawn across the sarcolemma of two adjacent fibres and the 
maximal fluorescent intensity of the line was identified and normalized to the vehicle mdx 





Western Blot Analysis 
Western blot analysis were used to determine relative protein levels of SERCA 
isoforms (SERCA1a and SERCA2a), SLN, calcineurin, utrophin, NFATc1 and p-NFATc1 in 




mice. For detection of SERCA 
isoforms, calcineurin, NFATc1 and p-NFATc1, samples were separated using standard SDS-
PAGE (7.5% total acrylamide) and transferred on to 0.2µm PVDF membranes. Detection of 
utrophin utilized a 6% total acryalmide gel that was transferred onto a 0.2µm PVDF 
membrane. For SLN, samples were separated with Tricine-based SDS-PAGE (13% gel) and 
transferred onto 0.2 µm nitrocellulose membrane. Membranes were probed with their 
corresponding antibodies for calcineurin (1: 1000), utrophin (1:500), NFATc1 (1: 5000), p-
NFATc1 (1:5000), actin (1: 10 000) and SLN (1: 50). Membranes were then washed and 
probed with secondary goat anti mouse IgG (SERCA isoforms, 1:20 000; calcineurin, 1: 5000; 
utrophin, 1:2000; p-NFATc1, 1:2000; actin, 1: 20 000) or goat anti rabbit (NFATc1, 1:2000; 
SLN, 1:2000). Antigen-antibody complexes were detected by either SuperSignal West 
Femto
TM
 substrate (Pierce; Thermo Fisher Scientific Inc., Grand Island, NY) for utrophin, SLN 
and p-NFATc1 or Luminata Forte
TM
 (Millipore, Billerica, MA) for SERCA1a, SERCA2a, 
calcineurin, and NFATc1. Quantification of optical densities was performed using GeneTools 
(Syngene, MD) and normalized to total protein content from ponceau staining. Pan actin was 
used as a loading control for SERCA1a due to the limited protein load which made ponceau 
staining unreliable in detecting total protein. The ratio of p-NFATc1 to total NFATc1was 
quantified and used as a marker of calcineurin signaling, with a lower ratio indicating higher 
calcineurin signaling and greater nuclear NFATc1 localization. See appendix for further 
Western blotting details. 
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Serum Creatine Kinase 
Serum creatine kinase (CK), a common measure to assess muscle damage, was 
measured in sham-injected and DFZ-injected animals of both genotypes (mdx & mdx/Sln
-/-
).  
Briefly, twelve mdx mice (six n=6 vehicle & n=6 DFZ) & twelve mdx/Sln
-/-
mice (n=6 vehicle 
& n=6 DFZ) were sacrificed via cervical dislocation, the thoracic cavity was opened and the 
heart was removed. Blood then pooled was collected into a syringe, allowed to clot on ice for 
10 minutes and was then spun down at 5000 g for 10 min at 4°C. The plasma was decanted and 
stored at -80°C until analysis. Serum CK activity was measured using a kinetic fluorometric 
assay as described previously [146]. This assay works based on the rate of production of 
NADPH from the following reactions.  
              
              
                           
            
          
                          
                
        
                              
 
The production of NADPH was measured on a fluorometer at 340nm for 5 minutes.To do this, 
5µL of serum was added to 1mL of solution mixture (Imidazole 25mM, MgCl2 2.5mM, N-
acteyl cysteine 5mM, glucose 5mM, NADP 500µM, AMP 1mM, ADP 500µM, glucose-6-
phosphate dehydrogenase (G-6-P-DH) 0.4U/mL, hexokinase 0.63U/mL), was allowed to 
equilibrate for 5 minutes. Creatine phosphate (15mM final concentration) was then added and 
200µL of the solution was loaded into a black 96well plate and read in triplicate. The rate of 
NADPH production was then converted into a concentration of creatine kinase by dividing the 




Statistical Analyses  
 The data are presented as mean ± standard error (SEM). Statistical significance was set 
at p≤0.05. Unless otherwise stated, all collected data were compared using a Two-Way 
ANOVA with treatment (VEH or DFZ) and genotype (mdx or mdx/Sln
-/-
) as factors. Post-hoc 
testing was done using a Neuman-Keul test to compare specific means, when appropriate. 
Trends in data were only labeled as such when p=0.05-0.1. Planned comparisons with two-
tailed t-test (one-tailed when specified) were utilized only when the literature or data within 
this thesis provided sufficient evidence to warrant further statistical examination.  
 
Results  
Physical Characteristics and Serum Creatine Kinase Levels  
Beginning at 4 weeks of age, mdx and mdx/Sln
-/-
 pups were injected with either VEH 
(saline) or DFZ, for 7 days. At time of sacrifice (5 weeks of age), mdx mice on average were 
lighter than mdx/Sln
-/- 
mice (Figure 3.1A, p=0.0078 mdx < mdx/Sln
-/-
). In addition, there was a 
trend where DFZ treated animals weighed less than VEH treated animal (p=0.0698; 
VEH>DFZ). Despite an initial difference in weight (see appendix S1.1), Figure 3.1B shows 




The absolute weight of the SOL, DIA and EDL muscles was measured and then 
normalized to body weight. For SOL, there was no effect of treatment (Figure 3.2, p>0.05) but 
there was a main effect of genotype for both absolute (Figure 3.2A, p=0.002) and relative 
(Figure 3.2B p=0.0072) muscle mass, which were greater in mdx/Sln
-/-
 compared to mdx. 
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Similar results were found for DIA, as there were no treatment effects (Figure 3.3, p>0.05) but 
there was a main effect of genotype with greater absolute (Figure 3.3A, p=0.0006) and relative 
(Figure 3.3B, p=0.0002) muscle weights in mdx/Sln
-/-
 compared with mdx. There were no 
differences in either absolute or relative EDL muscle weights between any groups (Figure 3.4; 
p>0.05). 
Serum CK, a marker of muscle breakdown or damage, was higher in mdx/Sln
-/-
 mice 
compared with mdx mice (main effect of genotype; Figure 3.5 p=0.0272, mdx<mdx/Sln
-/-
). 
Surprisingly, CK levels were elevated in DFZ treated groups compared with VEH (main effect 















































Figure 3.1: Absolute and change in (Δ) body weight of mdx and mdx/Sln
-/-
 mice treated 
with VEH or DFZ. (A) Body weight (g) of mdx and mdx/Sln
-/-
 mice at time of sacrifice shows 
significant main effect of genotype (p=0.0078, mdx < mdx/Sln
-/-
) and a trending main effect of 
treatment (p=0.0698, VEH>DFZ). (B) Change in body weight from start of treatment to time 
of sacrifice (g) of mdx and mdx/Sln
-/-
 mice. All values are presented as mean ± standard error. 

































































Figure 3.2: Absolute and relative SOL weight in mdx and mdx/Sln
-/-
 mice treated with 
VEH or DFZ. (A) Absolute muscle weight (mg) of SOL post treatment with VEH or DFZ. 
There is a significant main effect of genotype effect (p=0.002, mdx<mdx/Sln
-/-
). (B) SOL 
weight (g) normalized to body weight (g) post treatment shows a significant main effect of 
genotype (p=0.0072, mdx<mdx/Sln
-/-
). All values are presented as mean ± standard error. (n=8-




































































Figure 3.3: DIA absolute and relative weight of mdx and mdx/Sln
-/-
 mice treated with 
VEH or DFZ. (A)Absolute DIA weight (mg) and (B) relative DIA weight post treatment in 
mdx and mdx/Sln
-/-
 mice. There is a significant main effect of genotype for both absolute and 
relative DIA weight (p=0.006 & p=0.002 respectively, mdx<mdx/Sln
-/-
). All values are 



































































Figure 3.4: EDL absolute weight and relative muscle weight in mdx and mdx/Sln
-/-
 mice 
treated with VEH or DFZ. (A)Absolute weight of EDL (mg) and (B) relative EDL weight 
post treatment in mdx and mdx/Sln
-/-
























Figure 3.5: Serum CK levels in mdx and mdx/Sln
-/-
 mice after treatment protocol. 
Significant main effects of genotype (p=0.0272, mdx<mdx/Sln
-/-
) and treatment (p=0.0164, 







Histological Features of DMD in the Soleus and Diaphragm 
When examining the SOL muscle, there was a trend for a main effect of treatment, 
where DFZ treated groups showed improvements in centralized nuclei (Figure 3.6B; p=0.076 
VEH>DFZ).  There were no differences (p>0.05) in centralized nuclei between mdx and 
mdx/Sln
-/-
 mice. Total fibre number was not different between any of the groups (Figure 3.6C; 
p>0.05). 
In DIA, DFZ treatment decreased the presence of centrally nucleated fibres in both mdx 
and mdx/Sln
-/-
 mice compared to VEH (Figure 3.7A/B; main effect p=0.015, VEH>DFZ). A 
main effect of genotype was also observed, where mdx/Sln
-/-
 mice had an increased presence of 
centralized nuclei (p=0.0002, mdx<mdx/Sln
-/-
). Total fibre number was not affected by 
































































Figure 3.6: Centralized nuclei and total fibre number in SOL from mdx and mdx/Sln
-/-
 
mice treated with VEH or DFZ. (A) Representative images of H&E staining used for 
quantification of (B) centrally nucleated fibres where a trend for a main effect of treatment 
were observed (p=0.076, VEH>DFZ) and (C) total fibre number. All values are presented as 































































Figure 3.7: Centralized nuclei and total fibre number in DIA from mdx and mdx/Sln
-/-
 
mice treated with VEH or DFZ. (A) Representative images of diaphragm from H&E staining 
used for quantification of (B) centrally nucleated fibres where main effects of genotype 
(p=0.0002, mdx<mdx/Sln
-/-
) and treatment (p=0.015 VEH>DFZ) were observed and (C) total 
fibre number. All values are presented as mean ± standard error (n=6-8 per group). Scale bar 
depicts 100µm. 
 
Figure 3.8 shows that DFZ significantly decreases the infiltration of collagen in SOL of 
both mdx and mdx/Sln
-/-
 mice compared with VEH (main effect, p=0.0221; VEH>DFZ). 
Collagen infiltration in SOL was not different between genotypes (p>0.05). DFZ treatment also 
decreased collagen infiltration in DIA in both mdx and mdx/Sln
-/-
 mice (Figure 3.9, main effect 
p=0.003; VEH>DFZ). There is also a trend (p=0.07) for a main effect of genotype with DIA 
from mdx/Sln
-/-











































Figure 3.8: Collagen infiltration in SOL of mdx and mdx/Sln
-/-
 mice treated with VEH or 
DFZ. (A) Representative Van Gieson staining used for (B) quantification of collagen 
infiltration in mdx and mdx/Sln
-/-
 mice post DFZ or VEH treatment. There was a significant 
main effect of treatment (p=0.0221, VEH>DFZ). All values are presented as mean ± standard 











































Figure 3.9: Collagen infiltration in DIA of mdx and mdx/Sln
-/- 
mice after treatment 
protocol. (A) Representative images of Van gieson staining used for (B) quantification of 
collagen infiltration in mdx and mdx/Sln
-/-
 post DFZ or VEH treatment. There was a significant 
main effect of treatment (p=0.003, VEH>DFZ) and a trend for a main effect of genotype 
(p=0.07, mdx>mdx/Sln
-/-
). All values are presented as mean ± standard error (n=6-8 per group). 
 
Immunofluorescent Features of DMD in the Soleus and Diaphragm  
Immunofluorescent staining was used to quantify fibre type distribution, CSA and 
coefficient of variation in minimal Feret’s diameter in SOL (Figure 3.10 and Figure S1.2) and 
DIA (Figure 3.11 and Figure S1.3). In SOL, DFZ treatment decreased type IIX fibres 
proportions in both mdx and mdx/Sln
-/-
 mice compared to VEH (Figure 3.10B, p=0.0094; 
VEH>DFZ). There was a trend for a main effect of genotype effects for both IIX/IIB hybrid 
fibres (Figure S1.2, p=0.069) and IIB fibres (Figure 3.10B, p=0.0532) where mdx/Sln
-/-
 mice 
had increase proportions compared to mdx.  There were no differences (p>0.05) in type I, I/IIA, 
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IIA and IIA/X fibres between any groups. CSA of type I, IIA, and IIB was also not different 
(p>0.05) between any groups. There was a trend for an interaction effect for CSA of type IIX 
fibres (p=0.0765), whereby DFZ treatment increased CSA in mdx mice but decreased CSA in 
mdx/Sln
-/-
 mice compared with VEH (Figure 3.10C); however Newman-keul post-hoc 
comparisons showed no difference between groups (p>0.05). There was also a trend for an 
interaction effect in fibre size variability in the SOL, as measured by the coefficient of 
variation of minimal Feret’s diameter (Figure 3.10D, p=0.0903). Compared with VEH, the 
DFZ treatment increased variability in mdx mice and decreased variability in mdx/Sln
-/-
 mice. 
However, post hoc comparisons revealed no significant differences between groups (p>0.05).  
In the DIA, proportions of type I, IIA and IIB fibres were not altered by DFZ (p>0.05) 
or genotype (p>0.05). DFZ treatment increased IIX fibres in both mdx and mdx/Sln
-/-
 mice 
treated with DFZ (main effect, p=0.0246, VEH<DFZ). There was a main effect of genotype 
where mdx/Sln
-/-
 mice had increased proportions of type I/IIA fibres (p=0.0349) and IIA/IIX 
fibres (p=0.007) compared with mdx mice (Figure S1.3). There was a main effect of treatment 
where IIA/IIX fibres were increased after DFZ treatment compared to VEH (Figure S1.3, 
p=0.0295).  
There were no difference in CSA of any fibre type in DIA between any groups 
(p>0.05). Mdx/Sln
-/-
 mice had increased fibre size variability compared to mdx mice 
























































































Figure 3.10: Fibre type distribution, CSA and covariance of minimal Feret’s diameter in 
SOL muscles from mdx and mdx/Sln
-/-
 after treatment with VEH or DFZ. (A) 
Representative immunofluorescent images of SOL sections show type I fibres in blue, type IIA 
fibres in green, type IIX fibres in black and IIB fibres in red. Scale bar depicts 100µm. 
Quantification of (B) fibre type distribution, (C) CSA and (D) covariance of minimal Feret’s 
diameter. A significant treatment effect (p=0.0094 VEH<DFZ) was observed in the 
distribution of IIX fibres and a trend for a genotype effect in IIB fibres (p=0.0532, 
mdx<mdx/Sln
-/-
). A trend for an interaction effect in the CSA of IIX fibres (p=0.0765) and in 
covariance of minimal Feret’s diameter (p=0.0903) was observed. All values are mean ± 
standard error (n=8-9 per group).  
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Figure 3.11: Fibre type distribution, CSA and covariance of minimal Feret’s diameter of 
DIA from mdx and mdx/Sln
-/-
 mice after treatment with VEH or DFZ. (A) Representative 
immunofluorescent images of myosin heavy chain distribution show type I fibres in blue, type 
IIA fibres in green, type IIX fibres in black and IIB fibres in red. Scale bar depicts 100µm. 
Quantification of (B) fibre type distribution, (C) CSA and (D) fibre size variability measured 
by covariance of minimal Feret’s diameter. There was a significant increase in IIX fibres after 
DFZ treatment (p=0.0246, VEH<DFZ). Mdx/Sln
-/-
 mice have increased covariance of minimal 
feret’s diameter compared to mdx mice (p=0.0065, mdx<mdx/Sln
-/-
). All values are mean ± 









Calcineurin/NFAT Signalingin the Soleus and Diaphragm 
 
Western blot analyses of total NFATc1 and NFATc1-p in Sol from DFZ and VEH are 
shown in Figure 3.12. There were trends for main effects of treatment for both total NFATc1 
(Figure 3.12B, p=0.0836; VEH <DFZ) and NFATc1-p (Figure 3.12C, p=0.079l; VEH<DFZ), 
indicating that both total and cytosolic NFATc1 pools are increased by DFZ treatment. There 
was also a trend for a main effect of genotype for total NFATc1 (Figure 3.12B, p=0.0797), 
with content being lower in mdx mice compared to mdx/Sln
-/-
 mice. No genotype differences 
were observed in NFATc1-p (p>0.05). There were no significant effects of genotype (p>0.05) 
or treatment (p>0.05) for NFAT-p to total NFATc1 ratios (Figure 3.12D). Nuclear NFAT 
localization in SOL was also assessed using immunofluorescent staining of NFATc1 and DAPI 
(Figure 3.13). This analysis yielded a significant main effect of treatment with higher levels of 
NFATc1 and DAPI co-localization following DFZ compared with VEH, as measured by 
Pearson’s correlation coefficient (Figure 3.12D, p=0.018, VEH<DFZ). There were no 
genotype differences in NFATc1 and DAPI co-localization (p>0.05).  
Western blot analyses of total NFATc1 and NFATc1-p in DIA from DFZ and VEH 
treated mice are shown in Figure 3.14. Total NFATc1 levels were significantly higher in mdx 
mice compared to their mdx/Sln
-/-
 counterpart, regardless of treatment (Figure 3.14B, 
p=0.0017).  Similar results were found for phosphorylated NFATc1 content but there was only 
a trend for main effect of genotype (Figure 3.14C; p=0.0692, mdx >mdx/Sln
-/-
). As a result, the 
ratio of NFATc1-p to total NFATc1 was significantly higher in mdx/Sln
-/-
 compared with mdx 
mice (Figure 3.14D, p=0.047), an effect that was independent of treatment. However, when 
examined using immunofluorescence (Figure 3.15), the co-localization of NFATc1 and DAPI 



















































































Figure 3.12: Western blot analysis of total NFATc1, phosphorylated NFATc1 and ratio of 
NFATc1-p to total NFATc1 in SOL of mdx and mdx/Sln
-/-
 mice after treatment with DFZ 
or VEH. (A) Representative western blots of (B) total NFATc1 where there were trends for 
main effects of treatment (p=0.0836, VEH<DFZ) and genotype (p=0.0797, mdx<mdx/Sln
-/-
) 
and (C) phosphorylated NFATc1 where there was a trending main effect of treatment 
(p=0.0791, VEH<DFZ). (D) The ratio of NFATc1-p to total NFATc1 was calculated as a 
maker of nuclear NFAT localization. Total NFATc1 and FNATc1-p contents were normalized 












































































































Figure 3.13: NFATc1 localization in SOL sections from mdx and mdx/Sln
-/-
 mice after 
treatment with DFZ or VEH. (A) Representative images of NFATc1 localization show 
NFATc1 in green, α-dystroglycan in red and DAPI in blue. (B) Quantification of pearson’s 
coefficient of NFATc1 localization. A significant main effect of treatment effect was observed 
(p=0.018, VEH<DFZ). All values are presented as mean ± standard error (n=6 per group). 
















































































Figure 3.14: Western blotting analysis of total NFATc1, phosphorylated NFATc1and 
ratio of NFATc1-p to total NFAT in DIA from mdx and mdx/Sln
-/-
 mice after DFZ or 
VEH treatment. (A) Representative western blots of (B) total NFATc1 which was 
significantly higher in mdx mice compared with mdx/Sln
-/-
 mice (main effect of genotype, 
p=0.0017) and (C) phosphorylated NFATc1 where there was a trending main effect of 
genotype (p=0.0692, mdx>mdx/Sln
-/-
). (D) The ratio of NFATc1-p to total NFATc1 was 
calculated as a marker of nuclear NFAT localication and there was a significant main effect of 
genotype (p=0.047, mdx<mdx/Sln
-/-
). Total NFATc1 and NFATc1-p contents normalized to 























































































































Figure 3.15: NFATc1 localization in DIA sections from mdx and mdx/Sln
-/-
 mice after 
DFZ or VEH treatment. (A) Representative images of immunofluorescent detection of 
NFATc1, where NFATc1 is green, α-dystroglycan in red and DAPI is blue. (B) Quantification 
of pearson’s correlation coefficient of NFATc1 and DAPI localization.  All values are 
presented as mean ± standard error (n=6 per group). Scale bars depict 10µm. 
 
In the SOL, there were no differences in calcineurin content between groups (Figure 
3.16, p>0.05). In DIA, there was a trending interaction effect whereby calcineurin content 
appears to decrease with DFZ treatment in mdx mice, while content appears to increase in 
mdx/Sln
-/-
 mice (Figure 3.17, p=0.0940), however post hoc analysis shows no difference 









































Figure 3.16: Western blot analysis of calcineurin content in SOL from mdx and mdx/Sln
-/-
 
after treatment with VEH or DFZ. (A) Representative western blots of SOL and (B) 
quantification of calcineurin content which was normalized to total protein from ponceau stain. 











































Figure 3.17: Western blot analysis of calcineurin content of DIA muscles from mdx and 
mdx/Sln
-/-
 mice after VEH or DFZ treatment. (A) Representative western blotting of (B) 
calcineurin content from DIA which shows a trend for an interaction effect (p=0.0940) where 
DFZ decreased calcineurin content in mdx mice and increases content in mdx/Sln
-/-
 mice. 
Calcineurin content was normalized to total protein from ponceau stain. All values are mean ± 
standard error (n=8 per group). 
 
Unexpectedly, utrophin content assessed by Western blotting in both SOL and DIA was 
not different after treatment nor was there any effect of genotype (Figure 3.18B & Figure 3.20, 
p>0.05). Immunofluorescent detection of utrophin also showed there were no differences 







































Figure 3.18: Western blot analysis of utrophin content of SOL from mdx and mdx/Sln
-/-
 
mice after VEH or DFZ. (A) Representative western blots of utrophin in SOL of mdx and 
mdx/Sln-/- mice after treatment. (B) Quantification of immunoblot of utrophin normalized to 





















































Figure 3.19: Immunofluorescent detection of utrophin in SOL of mdx and mdx/Sln
-/-
 mice 
after treatment. (A) Representative images of utrophin and (B) quantification of utrophin 






































Figure 3.20: Western blotting of utrophin content in DIA in mdx and mdx/Sln
-/-
 mice after 
treatment with DFZ and VEH. (A) Western blots for utrophin were (B) quantified for 

























































Figure 3.21: Normalized fluorescent intensity of utrophin staining from DIA of mdx and 
mdx/Sln
-/-
 mice. (A) Representative immunofluorescent staining of utrophin from DIA 
sections was (B) quantified and normalized to mdx VEH group. Scale bars depict 25µm. All 
values are mean ± standard error (n=8 per group). 
 
Calcium Handling Proteins in the Soleus and Diaphragm 
DFZ or genotype did not change SERCA1a content in the SOL of mdx and mdx/Sln
-/-
mice (Figure 3.22C, p>0.05). A trend for a main effect of genotype was observed for 
SERCA2a content in SOL (Figure 3.23, p=0.0544; mdx>mdx/Sln
-/-
).  DFZ did not alter 
SERCA2a expression in the SOL (p>0.05). In the DIA, SERCA1a and SERCA2a content was 
not altered by DFZ (Figure 3.24C &D, p>0.05). A significant main effect of genotype was 
observed in SERCA1a content in DIA (Figure 3.23C, p=0.0174), where mdx/Sln
-/-
 mice had 
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decreased levels of SERCA1a content compared to mdx mice. No effect of genotype was 









































































Figure 3.22: Western blotting of SERCA1a and SERCA2a in SOL of mdx and mdx/Sln
-/-
 
mice after VEH or DFZ treatment. Representative western blots of (A) SERCA1a and (B) 
SERCA2a.  Quantification of (C) SERCA1a normalized to actin and (D) quantification of 
SERCA2a normalized to total protein from ponceau. A trend for a main effect of genotype is 
observed in SERCA2a content (p=0.0544, mdx > mdx/Sln
-/-
). All values are mean ± standard 












































































Figure 3.23: Western blot analysis of SERCA1a and SERCA2a content in DIA of mdx 
and mdx/Sln
-/-
 mice after treatment protocol. Representative western blots of (A) SERCA1a 
and (B) SERCA2a. Quantification of (C) SERCA1a content was normalized to actin and (D) 
SERCA2a content was normalized to total protein from ponceau stain. There is a significant 
genotype effect on SERCA1a content (p=0.0174, mdx>mdx/Sln
-/-
). All values are presented as 
mean ± standard error (n=8 per group). 
 
In mdx mice, DFZ significantly increased SLN content in SOL, when examined with a 
one tailed paired t-test (Figure 3.24B, p=0.0479). A one tailed t-test was used because evidence 
in the literature has shown glucocorticoid treatments to increase SLN content. However, as 
shown in Figure 3.25B, there was no change in SLN content in the DIA after the treatment 
protocol (p>0.05). See appendix for full Western blot including samples from mdx/Sln
-/-


































Figure 3.24: Western blot analysis of SLN content in SOL of mdx mice treated with VEH 
or DFZ. (A) A representative western of SLN in SOL. (B) Quantification of SLN content is 
normalized to total protein content from ponceau stain. All values are mean ± standard error.   






























Figure 3.25: Western blot analysis of SLN content in DIA of mdx after treatment with 
VEH or DFZ. (A) Representative western blot of SLN content in mdx mice. (B) 
Quantification of SLN content was normalized to total protein from ponceau. All values as 




   
Discussion 
The goal of this research project was to identify if the SERCA regulator, SLN, 
contributes to the positive effects of glucocorticoid treatment in the mouse model of Duchenne 
muscular dystrophy. Previous work from our lab has shown that mdx/Sln
-/-
 mice exhibit a 
worsened pathology than mdx mice, which was associated with blunted calcineurin/NFAT 
signaling [81].  Others have shown that glucocorticoids increase SLN content [80] and also 
activate the calcineurin/NFAT pathway in muscle [3]. Therefore, this thesis tested the 
hypothesis that ablation of Sln would result in blunted therapeutic effects of DFZ in mdx mice. 
As expected and consistent with the hypotheses DFZ improved the dystrophic phenotype of the 
mdx mice in the SOL, which was associated with increased SLN content and evidence for 
increased calcineurin/NFAT signaling. Despite histological improvements in the DIA, 
calcineurin/NFAT signaling and SLN content were not altered with DFZ. In contrast to the 
hypothesis, utrophin content was not altered after DFZ treatment in either SOL or DIA. 
Unexpectedly, mdx/Sln
-/-
 mice also showed histological improvements in SOL and DIA with 
DFZ suggesting that SLN is not required for those effects.  
Western blotting of the ratio of NFATc1-p to total NFATc1 is often used as a marker of 
calcineurin/NFAT activation and since DFZ has been shown to stimulate this pathway, it was 
expected that DFZ treatment would decrease this ratio. In contrast to this hypothesis this ratio 
was unaltered in SOL and DIA of both mdx and mdx/Sln
-/-
 mice. Although not significant, the 
visual trend of this ratio increasing in the SOL was opposite to the hypothesis, and thus the 
colocalization of NFATc1 and DAPI was used as another method to determine NFATc1 
localization. A potential reason for the conflicting Western blot data is that the rampant 
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immune response in DMD results in elevations in NFATc1 content from immune cells instead 
of muscle [147] and thus the use of colocalization of NFATc1 and DAPI within muscle fibres 
may provide a more valid marker of calcineurin/NFAT signaling in the myofibre. Using this 
technique, DFZ significantly increased colocalization of NFATc1 and DAPI in the SOL of mdx 
and mdx/Sln
-/-
 mice, but did not affect the DIA. The measurement of the DIA may be an 
underestimation of colocalization for the number of fibres analyzed. In the SOL 20 fibres are 
randomly selected and in the DIA only 40 fibres are analyzed. In terms of the total percentage 
of fibres quantified, the DIA has very little area that is evaluated compared to the SOL. This is 
the first study to show DFZ activates the calcineurin/NFAT pathway in mdx mice, as previous 
work only showed this in myotubes and measured only utrophin transcripts [3]. Other studies 
that utilized the mdx model have shown no difference in NFAT translocation after treatment 
with prednisone, the parent drug to DFZ [148]. This technique provides an improved measure 
of NFAT translocation compared to conventional Western blotting of total and phosphorylated 
NFAT and is in alignment with the study performed by St. Pierre et al. Future studies should 
quantify increased proportions of fibres in larger muscles, such as the DIA, to accurately 
determine the effect of DFZ in the DIA.  
The alterations of the activation of this pathway between muscles could be a result of 
differential calcineurin signaling between muscles. The DIA is known to have increased 
calcineurin activity compared to limb muscles [149]. This difference in calcineurin signaling 
could be a result of a number of factors including cytosolic Ca
2+
 levels, calcineurin activity, 
SLN content and SERCA activity.  
Glucocorticoids have been shown to increase cytosolic Ca
2+
 levels [150] and thus both 
genotypes may be susceptible to this first initial increase that would activate calcineurin and 
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downstream NFAT translocation. Furthermore, calcineurin signaling may also be altered if 
calcineurin content is changed. Here, calcineurin content in SOL was unaltered, while there 
was a trend for an interaction effect in the DIA, where mdx/Sln
-/-
 mice had increase calcineurin 
content with DFZ and mdx mice had a decrease in content. An increase in calcineurin content 
in the mdx/Sln
-/-
 DIA may compensate to increase calcineurin activity so that it is no different 
than the mdx mice. However, no differences in NFATc1 and DAPI localization were observed 
was similar in DFZ and VEH treated mice so differences in calcineurin signaling in these 
muscles cannot be explained by differences in calcineurin content. An upregulation of SLN 
was anticipated as glucocorticoids have been shown to increase SLN content in WT DIA [80] 
but in this experiment only the SOL experienced increased SLN content after DFZ. The extent 
of SLN upregulation could be limited in the DIA, due to higher basal expression of SLN in the 
DIA compared to SOL, as well as an overall upregulation of SLN in mdx mice [2]. With 
Western blotting the difference in basal expression was simple to see with the amount of 
protein necessary for detections. Only 5µg of protein had to be loaded to detect SLN in the 
DIA, while 12.5µg of protein had to be loaded in the SOL. With this increased basal content of 
SLN, there may be a limit to which SLN can be upregulated that is reached in the DIA but not 
yet in the SOL, and thus DFZ was able to stimulate SLN upregulation in the SOL.  
In theory, the increased SLN content in mdx SOL may have increased [Ca
2+
]i  which 
could explain the apparent activation of calcineurin as indicated by an increase in 
colocalization of NFATc1 and DAPI. However, since SLN content is not altered and 
calcineurin signaling is increased in mdx/Sln
-/-
 mice it seems that SLN content is not required 
for the effects of DFZ on calcineurin signaling. It is possible that decreases in SERCA activity 
or content could elevate cytosolic Ca
2+
 and increase calcineurin activity in both genotypes. A 
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decrease in SERCA1a and SERCA2a content was expected since glucocorticoids decrease 
SERCA content in DIA [80], and could also increase cytosolic Ca
2+
 levels and activate 
calcineurin in the mdx/Sln
-/-
 mice. However, SERCA content of either isoform was not altered 
by DFZ. Although no change in SERCA content suggests that SERCA activity would be 
unaltered, a measurement of SERCA activity would provide better understanding of SERCA 
activity and potential differences between genotypes. At this moment, the underlying 
mechanism for increased calcineurin signaling in mdx/Sln
-/-
 SOL is unknown.    
Collectively, these data are indicative of SLN not being involved in activating the 
calcineurin/NFAT pathway, as it was suggested in previous work in our laboratory [81]. It 
could be that an increase of SLN content in SOL was a product of upregulations of upstream 
factors such as myocyte enhancer factor 2 (MEF2), which is involved in muscle regeneration 
and is activated by the NFAT [151, 152]. However, if SLN is playing a role in activating 
calcineurin, compensatory adaptations in the mdx/Sln
-/- 
mice could not be ruled out. 
Upregulations of other SERCA regulators such as phospholamban (PLN), myoregulin (MLN) 
and DWORF [153, 154] could be a compensatory mechanism to elevate cytosolic Ca
2+ 
and 
activate calcineurin in the mdx/Sln
-/-
 mice. Increased SR leak or changes to Ca
2+
 handling 
proteins such as the ryanodine receptor or the voltage sensing dihydropyridine receptor, could 
result in increased Ca
2+
 release and increased cytosolic Ca
2+
. Additionally, store operated Ca
2+
 
entry, through increase Stromal interaction molecule 1(STIM1) content, are already elevated in 
mdx mice [155] and could have differences in expression in the mdx/Sln
-/- 
model. Alterations in 
other Ca
2+
 handling proteins in addition to SERCA regulators could provide compensatory 
responses in mdx/Sln
-/-
 mice to DFZ treatment which elevate cytosolic Ca
2+




The activation of the calcineurin/NFAT pathway is known to elevate utrophin content, 
whether through the chronic activation of calcineurin [101, 130, 131] or through 
glucocorticoids [3]. However, despite activation of calcineurin/NFAT pathway in the SOL, 
utrophin content is unaffected by DFZ in this thesis, regardless of muscle or method of 
detection. One possible explanation for the lack of change in utrophin, is that overall NFAT 
translocation was unaffected by DFZ. In this study only NFATc1 was utilized, as its 
translocations is necessary in the promotion of an oxidative phenotype [31, 93, 156], but other 
NFAT isoforms could be essential for the upregulation of utrophin and the mitigation of a 
dystrophic phenotype.  The utrophin A promoter has a binding site for NFAT, but it is 
unknown where this binding site is exclusive to NFATc1. It is plausible that other NFAT 
isoforms could bind to this region and alter utrophin promotion. NFATc1 to NFATc4 are all 
sensitive to calcineurin, and together these isoforms work in concert to bring about adaptation 
and regeneration of muscle, [90, 92, 93, 95, 157].  For example, NFATc2 is essential in the 
growth of fibres and the loss of NFATc2 results in reduced myofibre number and reduces CSA 
[158, 159]. SLN overexpression is shown to decrease the ratio of NFATc3-p to total NFATc3, 
indicating an increase in translocation of NFATc3 to the nucleus [105]. Other isoforms of 
NFAT were not measured in this study and thus it is unknown to what extent changes in each 
isoform are playing with respect to utrophin promotion. Although utrophin content is normally 
associated with type I fibres and myosin heavy chain I promotion is associated with NFATc1, 
individual knock down of NFAT isoforms 1-4 have shown blunting of the MHCI promoter 
[160] and thus have the potential to influence utrophin content. Future studies should examine 
the influence of DFZ on other NFAT isoforms and any alterations of downstream targets, such 
as utrophin.   
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This lack of utrophin upregulation is consistent with the unaltered type I and IIA fibre 
content. It was hypothesized that DFZ treatment would increase calcineurin activity, promoting 
a slow muscle phenotype (i.e. increase proportion of type I and IIA fibres), and that mdx/Sln
-/- 
mice would not have this same promotion. Contrary to this hypothesis, DFZ did not alter the 
presence of type I and IIA fibres in either muscle. This suggests that calcineurin activity was 
not sufficient to alter type I and IIA myosin heavy chain content. Unexpectedly, DFZ appeared 
to altered type IIX fibres in both the SOL and DIA muscles in both genotypes. Although 
calcineurin is a major regulator of fibre type [84], other fibre type regulators such as thyroid 
hormone [161], Ca
2+
/calmodulin-dependent kinase (CaMK) [162] and FOXO1, a member of 
the forkhead transcription factor forkhead box protein O family [163], also regulate fibre type 
transitions and alterations in these pathways could mitigate fibre type transitions. In the study 
that showed the calcineurin/NFAT pathway was activated by DFZ in vivo, myosin heavy chain 
distribution was never analyzed in any muscle [3] so it is unknown whether a slow muscle 
phenotype was promoted by DFZ. Studies that have a chronic activation of calcineurin (for 
example the CnA/mdx mice), show a significant increase in IIA fibres in skeletal muscle [101, 
131], while only one study has shown that type I fibres are actually decreased after one week 
of glucocorticoid treatments in the SOL of mdx mice [148]. In that study it was suggested that 
glucocorticoids tried to return fibre distribution to that of healthy WT tissue. As the SOL is 
primarily composed of myosin heavy chains I and IIA, this decrease in MHC IIX would be 
consistent with a return to a normal fibre distribution. Similarly, the increase in IIX fibre 
content in DIA with DFZ would be consistent with a return to a normal fibre distribution, as 
the DIA is mainly composed of type IIA and IIX fibres [164].  
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The calcineurin/NFAT pathway has also been implicated in muscle fiber growth [84, 
91]. It was hypothesized that DFZ treatment in mdx mice would have increased CSA area 
compared to VEH controls, and that mdx/Sln
-/-
 mice would not have this same increase. In 
contrast to the hypothesis, CSA was unaltered in both DIA and SOL of both genotypes, 
illustrating that DFZ had little effect on CSA. It is important to note that CSA is an unreliable 
measure when assessing treatment effects on dystrophic muscle but rather the variance 
coefficient of minimal Feret’s diameter is a sensitive measure that is used for quantitative 
measures of muscular dystrophy to assess heterogeneity of fibre size. Unexpectedly, variability 
in fibre size in the SOL seemed to be elevated with DFZ in mdx mice, but a decrease was 
observed in mdx/Sln
-/-
 mice, while the DIA showed no difference between groups. In similar 
studies, fiber size variability was improved with DFZ treatment [3] but it was measured using 
the deviation of CSA, instead of the covariance of minimal Feret’s diameter, which is  more 
sensitive to improvements in the phenotype from therapeutic interventions [17]. A covariance 
value over 250 is designated as dystrophic [165] but the average values from all groups are just 
above this cutoff. Based on the contradictory increase in fibre size variability in mdx SOL with 
DFZ and the lack of effect in DIA, DFZ may not have such a pronounced effect on fibre size 
variability.  
This thesis challenges whether the improvements in the dystrophic phenotype by DFZ 
are through the calcineurin/NFAT pathway in this time frame, as downstream targets such as 
utrophin content, type I and IIA fibre content and CSA area were not altered. Improvements in 
histological features occurred in both mdx and mdx/Sln
-/-
 SOL and DIA despite activation of 
this pathway only in the SOL. Consistent with the hypothesis, fibrosis and number of centrally 





mice, which could indicate these positive effects are through the immunosuppressive effects of 
glucocorticoids, instead of the activation of the calcineurin/NFAT pathway. . In DMD, 
repeated cycles of degeneration and regeneration of DMD results in sustained infiltration of 
immune cells that promotes fibrosis and increased centralized nuclei [166-169]. 
Glucocorticoids decrease this immune driven response by inhibiting the activity of pro-
inflammatory cytokines or upregulating the expression of anti-inflammatory proteins (reviewed 
in [170]). Possibly DFZ has similar effects in both mdx and mdx/Sln
-/- 
mice through reducing 
immune driven damage, which would be independent of SLN expression. DFZ treatment 
improved the appearance of centralized nuclei in DIA [3], but the effects are less pronounced 
in the SOL [148], which in this thesis only shows a trending improvement. This may be due to 
the milder severity of the dystrophic phenotype in limb muscles potentially due to the 
decreased loading on limb muscles [19, 171, 172], compared with DIA.  
Serum CK is a clinical measure of muscle breakdown. It was hypothesized that DFZ 
would decrease serum CK levels in the mdx mice, as glucocorticoids delay muscle breakdown 
[116, 124, 173]. In mice, CK is highly variable and thus the majority of studies in mdx mice 
concerning glucocorticoid treatment demonstrate no changes or trending decreases in CK 
levels [124, 174, 175]. However, in this study serum CK levels were increased by DFZ 
treatment compared to VEH controls in both mdx and mdx/Sln
-/-
 mice. It is unknown why CK 
levels were higher following DFZ treatment but duration of the treatment may play a factor. If 
given a longer duration treatment, serum CK levels could possibly decrease after an initial 
increase, but this remains to be seen.  
Body weight after DFZ treatment also displays contradictory results to the literature. 
One of the major reported side effects of glucocorticoids in humans is weight gain [116, 175], 
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yet in this study, although only a trend, DFZ treated animals weighed less than the VEH group. 
The results here are consistent with a previous study in mdx mice, in which animals that were 
treated for 4 weeks with DFZ gained less weight than controls [124]. The length of treatment is 
a major difference between the animal studies and many human studies. Human DMD studies 
often treat patients with low dosage (<10mg/kg body weight) glucocorticoids for at least a year 
and typically document weight gain after 12 months of treatment [116, 128, 175].  The cause of 
this decreased body weight cannot be attributed to changes in muscle weight of SOL, DIA and 
EDL as DFZ did not alter muscle weight, although other muscles may be altered with DFZ. 
Instead these changes in body weight could be a result of alterations in adiposity and organ 
weight. Monitoring body composition via computed tomography during the course of 
treatment would provide better understanding in changes in body compositions that could 
affect overall weight.  
This is the first study that examined DFZ treatment in mdx and mdx/Sln
-/-
 mice, but 
other work from our laboratory has examined the mdx/Sln-/- mice at a later age (3-6 months). 
Basal genotype differences were observed in collagen infiltration in the DIA, serum CK, fibre 
type distribution and NFATc1-p to total NFATc1 ratios in the expected manner as previously 
shown by Fajardo et al. However, there were several unexpected differences to weight and 
muscle mass, centralized nuclei, fibre size variability, CSA, calcineurin signaling and utrophin 
content in comparison to previous examination of this line. Mdx/Sln
-/- 
mice were shown to have 
a blunted calcineurin/NFAT signaling cascade that results in a shift from slow-to-fast muscle 
phenotype, diminished CSA, increased fibre size variability, higher ratios of NFATc1-p to total 
NFATc1, and decreased utrophin content in comparison to mdx controls [81].  The blunting of 





 and a worsened muscle phenotype.  These earlier observations drove 
a number of the hypothesis generated based on basal genotype differences, including muscle 
phenotype (centralized nuclei, collagen infiltration and fibre type distribution) and underlying 
calcineurin activity.  
The most surprising difference between these studies was that mdx/Sln
-/-
 mice appeared 
to have minimal blunting of the calcineurin NFAT system as utrophin content and CSA was 
unaltered, although a shift from slow-to-fast fibre type distribution was exhibited. A slow-to-
fast shift in fibre type was consistent with the hypothesis as the SOL exhibited increases in IIX, 
IIB and hybrid IIX/IIB fibres, while there were minor increases in hybrid I/IIA and IIA/IIX 
fibres in the DIA. This shift is consistent with a worsened pathology as type II fibres are more 
susceptible to damage in DMD [176], yet utrophin content and CSA was unaltered between 
genotypes, which could be suggestive of limited blunting of the calcineurin/NFAT system.  
Interestingly and in complete contradiction to the previous study of mdx/Sln
-/-
 mice, 
centralized nuclei are not different compared to mdx mice in the SOL and are increased in the 
DIA. The increase in centralized nuclei observed in mdx/Sln
-/-
 DIA may be due to their age and 
regenerative capacity. At this time point, regeneration is ongoing and thus the appearance of 
centrally nucleated fibres is expected. The elevation of regenerating fibres could indicate 
increases in muscle breakdown, which would be consistent with a worsened pathology. In 
contrast, a lack of centralized nuclei in the older age group may be indicative of a failure of 
regeneration. It is unlikely that satellite cell pools have been exhausted at this time point, as 
pools remain relatively unchanged despite the progression of DMD [177, 178]. It is plausible 
that there is some impairment in regeneration at this time point that has not yet developed in 
the younger mdx/Sln
-/-
 mice.  
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Finally, body and muscle weight between the mdx and mdx/Sln
-/-
 was unexpectedly 
different compared to what was known in the older age group [81].  Interestingly, mdx/Sln
-/-
 
mice were consistently larger than mdx mice through the treatment protocol (Appendix S1.1), 
though weight gain over the week was not different between genotypes. These differences in 
body weight between mdx and mdx/Sln
-/-
 could partly be due to larger muscle masses in 
mdx/Sln
-/-
 mice as both DIA and SOL (but not EDL) masses were greater compared to mdx 
mice. Other components of body composition, such as adiposity and muscle edema, could also 
influence differences in body weight between genotypes and should be investigated in future 
studies.  
One factor that could explain these differences in pathology and anthropometrics is the 
age that the mice were studied at.  Here, 4-5 week old mice were studied whereas in the 
previous study of mdx/Sln
-/-
 [81], mice were examined at 3-6 months of age.  The age of mice 
for this thesis was chosen as they would be aged similarly to those used by St. Pierre and 
colleagues which showed that DFZ increased utrophin content through the calcineurin/NFAT 
pathway [122]. Although mdx mice have a milder phenotype in limb muscles [142], they 
undergo bouts of degeneration and regeneration between 3-7 weeks of age [20, 42] that is 
similar to human DMD patients. This chosen age puts the animals in this window of 
degeneration and regeneration that would allow for the effect of glucocorticoid steroids to be 
more correlative to human DMD. At 3-6 months of age, mdx mice are within a plateau period 
where muscle regeneration is able to mitigate disease progression [43, 164]. This thesis 
challenges whether improvements in the dystrophic phenotype by glucocorticoid treatments are 
through the calcineurin/NFAT pathway when treatment protocols are short. Given longer 
treatment protocols downstream targets of the calcineurin/NFAT pathway, such as utrophin, 
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may be improved. In addition, this study shows that SLN may not be involved in the beneficial 
effects of DFZ, as minimal differences between mdx and mdx/Sln
-/- 
mice were observed. 
However, this study provides in vivo evidence that DFZ does stimulate calcineurin signaling 
and that glucocorticoids increase SLN protein content.  
This thesis challenges whether improvements in the dystrophic phenotype by 
glucocorticoid treatments are through the calcineurin/NFAT pathway when treatment protocols 
are short. Given longer treatment protocols downstream targets of the calcineurin/NFAT 
pathway, such as utrophin, may be improved. In addition, this study shows that SLN may not 
be involved in the beneficial effects of DFZ, as minimal differences between mdx and mdx/Sln
-
/-
 mice were observed. However, this study provides in vivo evidence that DFZ does stimulate 
calcineurin signaling and that glucocorticoids increase SLN protein content.  
In summary, although SLN content is elevated in the SOL of mdx mice after DFZ 
treatment and the calcineurin/NFAT pathway is activated, utrophin content was not altered. 
Despite the histological improvements, calcineurin signaling was not stimulated by DFZ in the 
DIA. Based on this thesis, SLN may not play a in the positive effects of DFZ treatment. 
 
Future Directions  
 In the future, I believe there is much to be done in investigating the role of SERCA 
regulatory proteins in the progression of DMD. Identifying the underlying mechanisms for 
SLN upregulation after glucocorticoid treatment may provide better understanding of the role 
of SLN in disease treatment. Despite a measurement of SERCA content, SERCA activity was 
not measured in this study, and therefore it is unknown whether SERCA uptake is further 
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impaired by the increased SLN content after DFZ treatment. In unpublished data from Fajardo 
et al., maximal SERCA activity is not different between mdx and mdx/Sln
-/-
 mice [4]. A 
measure of SERCA activity and Ca
2+ 
uptake would provide better understanding of SERCA 
function and Ca
2+ 
levels in the dystrophic muscle after treatment. Techniques already 
implement in this laboratory could be utilized in future studies [81, 140]. Along the same line, 
a major limitation of this thesis is the lack of intracellular Ca
2+
 measurement that would 
provide sufficient evidence to show that SLN can increase cytosolic Ca
2+
 that would then 
activate calcineurin and downstream signaling. It is assumed that an upregulation of SLN and 
corresponding inhibition of SERCA would elevate cytosolic Ca
2+ 
that would then activate 
calcineurin. Intracellular measures of Ca
2+ 
have been performed and quantified previously in 
mdx isolated single fibres using Indo-1, a Ca
2+





dynamics during depolarization [179].  
 This thesis also defines calcineurin activity solely through NFATc1 translocation, but 
other NFAT isoforms, namely NFATc2-c4 are sensitive to calcineurin [90, 92, 93, 158]. 
NFATc1 was chosen for its promotion of an oxidative phenotype [90, 96, 97], yet Sln
OE
 mice 
which have a shift to an oxidative phenotype, have an increase NFATc3 translocation [105]. 
NFATc3 is involved with myoblast differentiation in synergy with STIM1 [180] and is 
responsive to over expression of SLN [105]. Other isoforms of NFAT may also affect muscle 
phenotype. NFATc2, for example, is involved with myoblast fusion and muscle growth; 
ablation of it results in decrease CSA and muscle fusion [158]. It was suggested that NFATc2 
and NFATc3 may aim to preserve muscle mass as part of a stress-response mechanism [181]. 
Given that, translocation of other NFAT isoforms may better identify differences between 
treatment effects in mdx and mdx/Sln
-/-
 mice. Future studies should examine the effect of Sln-
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ablation in all NFAT isoforms, as they direct different aspects of muscle growth, development 
and adaptation.  
 Finally, given the limited effect of DFZ in activating the calcineurin/NFAT pathway, 
treatment durations should be lengthened to fully identify if DFZ can stimulate this pathway 
and increase utrophin content. As described earlier, treatment with glucocorticoids in human 
DMD patients is much longer [116, 175], thus 7 days of DFZ treatment may not be sufficient 
to fully activate calcineurin/NFAT signaling. St. Pierre et al., utilized a varying lengths of 
treatments (1-4 weeks), where animals were given DFZ or a VEH once every other day [3]. 
After one week, histological benefits (centralized nuclei and fibre size variability), while 
increases utrophin A mRNA took approximately 8 days [3]. Time-release pellets of DFZ or 
prednisolone, a water soluble form of prednisone, could be used for longer durations in place 
of injections.   
 
Conclusions 
 The results obtained from this thesis provide further evidence that DFZ stimulates 
calcineurin activity in mdx mice. This thesis compared the treatment effects of DFZ in both 
mdx and mdx/Sln
-/-
 mice, as DFZ is shown to increase calcineurin activity which has been 
shown to mitigate the dystrophic phenotype through the promotion of utrophin [3]. 
Glucocorticoids have been shown to increase SLN content [80] and mdx mice already have an 
intrinsic upregulation of SLN [2] potentially functioning to activate the calcineurin/NFAT 
pathway. Given that mdx/Sln
-/-
 mice that already have blunted calcineurin/NFAT signaling, it 
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was hypothesized that mdx/Sln
-/-
 treated mice would not show the same improvements as the 
treated mdx mice.  
 This study demonstrates that DFZ improves some of the histological features of the 
dystrophic phenotype, namely centralized nuclei and collagen infiltration. The hypothesized 
fast-to-slow fibre type transition and decrease in fibre size variability by DFZ was not observed 
in either muscle examined. DFZ did stimulate calcineurin activity in both mdx and mdx/Sln
-/-
 
mice but downstream utrophin content was not altered. SERCA content was not altered in 
either genotype by the treatment, but potential elevations in cytosolic Ca
2+
 could be a result of 
increased SLN content by DFZ in the SOL. At this point, the data does not support the view 
that SLN is involved with the positive effects of DFZ treatment, as both mdx and mdx/Sln
-/-
 
mice have improvements in the dystrophic phenotype and activation of the calcineurin/NFAT 
cascade. Given that is treatment protocol was for a short duration, the positive effects seen here 
may be a result of an immunosuppressive effect of DFZ. Given more time, improvements in 
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Appendix A: Supplementary Material for Thesis  


























Figure S1.1: Body weight monitoring during injection protocol. A main effect of genotype 
indicates that mdx/Sln
-/-
 mice are heavier than mdx mice throughout the treatment protocol 
(p<0.05, mdx<mdx/Sln
-/-



























Figure S1.2: Distribution of all fibre types in SOL of mdx and mdx/Sln
-/-
 after treatment 
protocol. A trend of genotype was observed in IIX/IIB fibres (p=0.069, mdx<mdx/Sln
-/-
). All 



























Figure S1.3 Distribution of all fibre types in DIA of mdx and mdx/Sln
-/-
 after treatment 
protocol. A main effect of genotype in I/IIA and IIA/IIX fibres (p<0.05, mdx<mdx/Sln
-/-
) was 
observed. Main effect of treatment was observed in IIA/IIX fibres (p<0.05, VEH<DFZ). All 







WC LC mdx VEH mdx DFZ mdx/Sln
-/- VEH mdx/Sln-/- DFZ
10kDa-
A
WC LC mdx VEH mdx DFZ mdx/Sln




Figure S1.4: Full western blot of SLN content in SOL and DIA from mdx and mdx/Sln
-/-
 

















Appendix B: Breeding Strategy and Genotyping Protocol for mdx and mdx/Sln
-/- 
 
Generation of mdx and mdx/Sln
-/-
mice adapted from [81] 




 (mdx) colonies we first 





From these animals, an F1 offspring that are either female hemizgous mdx or male 
heterozygous mdx were obtained. All F1 offspring were heterozygous for Sln (Sln
+/-
). Next, we 
crossed F1offspring, from separate breeding pairs, to obtain our F2 generation. 
 
F2 offspring had a variety of genotypes including our experimental animals, 
mdx and mdx/Sln
-/-
. To adhere to the guidelines outlined by the Canadian Council of Animal 
Care and the University of Waterloo Animal Care Committee to reduce the amount of animals 
culled; two separate subset colonies were created to generate the experimental animals. These 
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: For this subset 
colony a WT (dystrophin positive) male mice from F2 were bred with heterozygous mdx 
females from F2. Both the sires and dams were homozygous for Sln
-/-
. This yielded our 
experimental mdx/Sln
-/-
 used in this study.  
 
mdx: For this subset colony a WT (dystrophin positive) male mice from F2 were bred with 
heterozygous mdx females from F2. Both sires and dams were homozygous for Sln
+/+
. This 
yielded our experimental mdx/Sln
+/+
 used in this study.
 
Note: Because crosses were bred from previous generations, the strain is a 50:50 mix of 
C57BL/10Scn:C57BL6/J). To prevent genetic drift, the mdx and mdx/Sln
-/-
 subset colonies 














High DNA Extraction Protocol 
Buffers: 
 
Mouse Ear-notch/Tail DNA Isolation Buffer 
0.5% SDS 
0.1M NaCl 
0.05M Tris base (pH 8.0) 
2-4mM EDTA 
Set final pH to 8.0. 
 
8M Potassium Acetate 
157.02g in 200mL dH20 (autoclaved water) 
 
1. Add Proteinase K (Sigma-Aldrich) to mouse ear-notch/tail DNA Isolation Buffer (see recipe 
below) at a concentration of1.0 mg/ml and mix. 
2. Add 200ul of solution to each Eppendorf tube with sample (ear notch/tail clip). Place 
tubes in a conical tube. 
3. Immediately place tubes in a water bath set to 63°C. Let tissue digest overnight. 
4. Add 37.5ul of 8M potassium acetate to each tube. 
5. Add 500ul of chloroform to each tube. Vortex for 5-10 mins.  
6. Spin 5-8mins at 9,000 g. 
7. Pipetter aqueous top layer in a new Eppendorf tube. There should be approximately 
200ul. 
8. Add 2 volumes (if you get 200ul from step 7 then you add 400ul) of 100% ethanol at 
room temperature. Mix by inverting. 
9. Spin at 14000 rpm for 20min at 4°C. 
10. Remove the supernatant and air dry for 2-3 mins. 
11. Add 30 ul of Autoclaved Water. 
12. Dilute to 20ng/µl concentration with autoclaved water after determining concentration in a 
Nanodropper 2000  
 
Table S2.1: Forward and reverse primers for mdx mice detection 





(DL1509) 134 bp 
 
Mdx Reverse 
(DL1573) 117 bp 
5’GCG CGA AAC TCA AAT ATG CGT GTT AGT GT-3’ 
 
 
5’-GAT ACG CTG CTT TAA TGC CTT TAG TCA CTC AGA 
TAG TTG AAG CCA TTT TG-3’ 
 











All mice were ear notched at 3 weeks of age and the DNA was extracted using the protocol 
described above. PCR was performed to amplify the DNA of interest. 40ng of DNA was added 
to Taq DNA polymerase mix (EP0402, Thermo Scientific Fermentas, Canada) containing Taq 
Buffer with (NH4)2S04 buffer (diluted to 1X), 4mM MgCl2, 200 μM dNTP (R0192, Thermo 
Scientific Fermetas), 0.625 units of Taq DNA polymerase, and 0.66 μM of the appropriate 
forward and reverse primers (listed below). Samples were then placed in a thermal cycler (MJ 
MINI, Bio- Rad Canada) and underwent their 
respective PCR reactions (protocol below). The primers used in this reaction were based from a 
competitive PCR reaction that uses the common forward primer established by Shin et al 
(listed below). The amplified products were then separated on a 3% agarose gel (in 1X TBE) 
containing 0.01% ethidium bromide (Bioshop, Canada) for 80 min at 100V. The gel is then 
imaged using a bio-imaging system (Syngene, Frederick, MD).  
 
Table S2.2: PCR cycle for mdx mice. 
 Temperature (°C) 
 
Time Number of cycles 
mdx 
 1. Denaturation 
 2. Denaturation 
 3. Annealing 
 4. Extension 
 5. Final Extension 

































Appendix C: Western Blotting Protocols 
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